
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc showed a slightly improved financial performance for 2Q25, with a net loss of $1.14 per share compared to an estimated loss of $1.22 per share, indicating better-than-expected management of expenses. The positive results from the clinical trials of its candidate OKI-219, which demonstrated high tolerability across all dose levels without significant adverse events, further support the company's strong position in the biopharmaceutical sector. The company's focus on developing precision medicines targeting underserved cancer therapies positions it well for potential future growth and success in the market.
Bears say
OnKure Therapeutics is projected to incur a significant net loss of $4.56 per share for the full year 2025, a slight improvement from the previous estimate of $4.75 per share. The company faces considerable risks, including potential negative clinical outcomes with its lead asset, OKI-219, and the possibility of delays in advancing its pipeline candidates into critical regulatory programs. Additionally, challenges related to timely regulatory approvals and increasing competition from other mutant-selective PI3Kα inhibitors further contribute to a negative outlook on the stock's performance.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares